PharmaCyte Biotech, Inc. (PMCB)
Valuation Overview•Is PharmaCyte Biotech, Inc. Overvalued or Undervalued?
Trading at a relative discount to industry peers, suggesting a specific risk premium is applied.
Fragile underlying quality score of 32/100; weak margins or elevated debt leverage warrant caution.
Wall Street forecasts a balanced outlook with consensus price targets near the current price.
Verdict: Mixed fundamental profile with offsetting strengths and weaknesses.
Wall Street sentiment is generally neutral. This outlook is strongly supported by highly attractive capital returns, driven by a balanced mix of reliable dividends and share buybacks.
PMCB struggles with subpar profitability and pressured margins. This is backed by a fortress balance sheet, holding significant net cash ($15M) and minimal debt risk.
The company maintains stable top-line performance paired with stable bottom-line earnings.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | — | — | — | — | |
| EBITDA | -$2.1M | — | — | — | — | |
| Net Income | -$1.6M | +9085.0% | — | — | — | |
| EPS (Diluted) | $-0.17 | +277.2% | — | — | — | |
| Free Cash Flow | -$787K | -38.4% | +10.2% | -5.0% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | — | — | — | — |
| Operating Margin | — | — | — | — |
| Net Margin | — | — | — | — |
| FCF Margin | — | — | — | — |
Total return is -27.5% (1Y), lagging the benchmark by -48.4%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | +4.1% | -3.3% | — |
| 1Y | -27.5% | -48.4% | — |
| 3YCAGR | -35.6% | -55.4% | — |
| 5YCAGR | -48.2% | -58.5% | — |
| 10YCAGR | -37.4% | -51.3% | — |
The S&P 500 is at 30.6x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about PharmaCyte Biotech, Inc. (PMCB) valuation, health, and returns.
Based on peer relative multiples, PharmaCyte Biotech, Inc. appears Limited: Cheap versus peers compared to industry peers.
PharmaCyte Biotech, Inc. has multiple valuation anchors: Peer Relative Fair Value: $99.65. A convergence of these signals offers higher conviction.
PharmaCyte Biotech, Inc. displays weak financial health with a composite quality score of 32/100, supported by a Altman Z-Score of -0.5 (distress zone), Piotroski F-Score of 4/9, Return on Invested Capital (ROIC) of -25.2%.
PharmaCyte Biotech, Inc. pays a 20.0% dividend yield, covered by a 4% payout ratio with 2 years of growth, supplemented by a 100.0% buyback yield.
PharmaCyte Biotech, Inc.'s current growth trajectory is Stable. The company achieved N/A 1Y revenue growth and +277.2% 1Y EPS growth, compared to its 3Y revenue CAGR of N/A.
Wall Street consensus is Hold based on 0 analysts. The consensus price target represents a N/A change from current levels.
Investment risks for PharmaCyte Biotech, Inc. include: -46.7% 1-year max drawdown, high beta (1.38x market volatility), elevated distress risk. Volatility risk is characterized by a beta of 1.38x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.